Panacea Life Sciences Holdings Q2 FY22: revenue $469K, up 50%; diluted EPS −$0.13

Key figures from this report

These are the numbers Panacea Life Sciences Holdings reported for Q2 FY22, the quarter ended Jun 30, 2022, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Revenue$469K+50% from $313K in Q2 FY2110-Q income statement, on EDGAR
2. Net income−$2.0M−7309% from $27K in Q2 FY2110-Q income statement, on EDGAR
3. Diluted EPS−$0.13Against $0.00 in Q2 FY2110-Q income statement, on EDGAR
4. Cash and cash equivalents$37K−72% from $131K in Q2 FY21Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
5. Cash from operations−$729KAgainst −$1.9M in Q2 FY2110-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables